Transgenomic MX-ICP Liquid Biopsy Tests
Transgenomic has launched its MX-ICP CRC Analysis and MX-ICP Melanoma Analysis. These two new liquid biopsy cancer panels are based on the company's Multiplexed ICE COLD-PCR (MX-ICP) technology.
MX-ICP CRC Analysis is a comprehensive panel that tests for the relevant mutations in a range of actionable genes that are among the most common gene mutations in colorectal cancer. These include KRAS and NRAS exons 2, 3, and 4; BRAF exon 15; PIK3CA exons 9 and 20; and EGFR exon 12 (S492R).
MX-ICP Melanoma Analysis is a panel that tests for BRAF exon 15 and NRAS exon 2 and 3 mutations, which have been identified in approximately 50 percent to 75 percent of malignant melanoma tumors, and are associated with differential response to treatment.
The panels are available for clinical use through Transgenomic's Oncology CLIA laboratory in Omaha, Nebraska.